JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Dyadic, we, us, our, or the Company) (Nasdaq: DYAI), a pioneering biotechnology firm, has announced that its Chief Executive Officer, Mark Emalfarb, will be presenting at the highly anticipated 2025 World Vaccine Congress in Washington, D.C.

The World Vaccine Congress is scheduled to take place from April 22 to April 24, 2025, bringing together leaders in the vaccine industry to discuss advancements, challenges, and innovations in vaccine technology. Mr. Emalfarb will take the stage on Wednesday, April 23, 2025, from 12:40 PM to 1:10 PM in Room 202A, focusing his presentation on two pressing topics: avian influenza (H5N1) and future pandemic preparedness.

During this crucial session titled, C1 Platform: The Urgent Need for Smarter Biomanufacturing A Call to Action on Avian Influenza (H5N1) & Future Pandemics, Mr. Emalfarb will unveil new preclinical research that highlights the capabilities of Dyadics proprietary C1 expression platform. This platform has shown remarkable promise in producing non-mRNA antigens and reagents essential for vaccine production.

We are excited to share the latest preclinical data from multiple studies demonstrating that Dyadics proprietary C1 platform enables the production of non-mRNA antigens that elicit high neutralizing antibodies, stated Mr. Emalfarb. He emphasized the platform's potential to facilitate rapid and cost-effective production of critical antigens, reagents, and cell culture media. These advancements are vital in addressing the significant global health challenges posed by avian influenza and future pandemics, enabling a more robust global health infrastructure through scalable and efficient biomanufacturing practices.

In addition to the presentation, Dyadics management team will be engaging with attendees throughout the conference. Interested parties can arrange meetings by reaching out to the company via email at assistant@dyadic.com, or they can visit the companys booth (#654) during the event.

About Dyadic International, Inc.

Dyadic International, Inc. is a leading biotechnology company that harnesses its innovative microbial production platforms to develop commercial cell lines for the large-scale manufacture of proteins. These proteins are used in a variety of applications, including human and animal vaccines and therapeutics, as well as in non-pharmaceutical sectors such as food, nutrition, and wellness.

The companys microbial gene expression and protein production technologies are based on the highly productive fungus, Thermothelomyces heterothallica (previously known as Myceliophthora thermophila). The flagship C1-cell protein production platform is built on an industrially proven microorganism (C1) that enhances the speed of development, lowers production costs, and potentially improves the efficacy of biologic vaccines and drugs, all while offering flexible commercial scales for the human and animal health markets. Dyadic has also introduced the Dapibus protein production platform, which enables the rapid development and large-scale manufacturing of low-cost proteins, metabolites, and other biological products for applications in the food and wellness sectors.

Dyadic is committed to leveraging its microbial platform technologies across a wide range of applications, including human and animal vaccines, therapeutics, and various nutritional products.

For more information about Dyadic International, please visit Contact:

Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com